REGN vs BIIB

For growth investors, Biogen Inc.

(BIIB) is the stronger pick with 1. 4% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 4x trailing P/E (15. 6x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 4x versus Biogen Inc. at 21. 6x. On forward P/E, Biogen Inc. is actually cheaper at 13. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +45. 4%, compared to -29. 9% for Biogen Inc. (BIIB). Over 10 years, the gap is even starker: REGN returned +96. 0% versus BIIB's -27. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 64β versus Regeneron Pharmaceuticals, Inc. 's 0. 81β — meaning REGN is approximately 26% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 38% for Biogen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Biogen Inc.

(BIIB) is pulling ahead at 1. 4% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Regeneron Pharmaceuticals, Inc. grew EPS 8. 2% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 13. 2% for Biogen Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus 19. 1% for BIIB. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 0x forward P/E versus 15. 6x for Regeneron Pharmaceuticals, Inc. — 2. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REGN: 20. 1% to $865. 68.

In this comparison, REGN (0.

5% yield) pays a dividend. BIIB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Biogen Inc.

(BIIB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64)). Both have compounded well over 10 years (BIIB: -27. 7%, REGN: +96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: REGN is a mid-cap deep-value stock; BIIB is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.